Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature

被引：1

作者：

Ishikawa, Natsuki ^{[1
]}

Kamimura, Kenya ^{[1
,2
]}

Endo, Saori ^{[1
]}

Ishii, Soichi ^{[1
]}

Ogawa, Kazuya ^{[1
]}

Sakai, Norihiro ^{[1
]}

Abe, Hiroyuki ^{[1
]}

Ko, Masayoshi ^{[1
]}

Shibata, Osamu ^{[1
]}

Koseki, Youhei ^{[1
]}

Yokoyama, Junji ^{[1
]}

Sakamaki, Akira ^{[1
]}

Terai, Shuji ^{[1
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan

[2] Niigata Univ, Dept Gen Med, Sch Med, Niigata, Japan

来源：

INTERNAL MEDICINE | 2022年 / 61卷 / 21期

关键词：

hepatocellular carcinoma; metastasis; adrenal gland; atezolizumab plus bevacizumab;

D O I：

10.2169/internalmedicine.9341-22

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metastases. We herein report a case of HCC in a 59-year-old man with intrahepatic lesions treated successfully by hepatic arterial chemoembolization, radiotherapy, and sorafenib; the extrahepatic lesion in the adrenal gland was treated by atezolizumab plus bevacizumab. The patient showed a tumor-free condition for one year. We have summarized the clinical course and reviewed the literature to underscore the efficacy of atezolizumab plus bevacizumab for treating extrahepatic lesions of HCC.

引用

页码：3233 / 3237

页数：5

共 12 条

[1] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
D'Alessio, Antonio
Cammarota, Antonella
Zanuso, Valentina
Pressiani, Tiziana
Personeni, Nicola
Rimassa, Lorenza
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
[2] Immune Checkpoint Inhibitors in the Treatment of HCC
Donisi, Clelia
Puzzoni, Marco
Ziranu, Pina
Lai, Eleonora
Mariani, Stefano
Saba, Giorgio
Impera, Valentino
Dubois, Marco
Persano, Mara
Migliari, Marco
Pretta, Andrea
Liscia, Nicole
Astara, Giorgio
Scartozzi, Mario
[J]. FRONTIERS IN ONCOLOGY, 2021, 10
[3] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Mulla, Sohail
Wang, Yulei
Lim, Ho Yeong
Zhu, Andrew X.
Cheng, Ann-Lii
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
[4] The role of microRNAs in liver cancer progression
Huang, S.
He, X.
[J]. BRITISH JOURNAL OF CANCER, 2011, 104 (02) : 235 - 240
[5] Imamura Ichiro, 2003, Kurume Medical Journal, V50, P41
[6] Kanomata Hiroyuki, 2016, Gan To Kagaku Ryoho, V43, P1594
[7] Spinal Cord Compression as Initial Presentation in Hepatocellular Carcinoma
Kaur, Jasmeet
Malik, Ambreen
Kaur, Mehrvaan
Goodman, Judie
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
[8] Kondo Hiroki, 2019, Gan To Kagaku Ryoho, V46, P2527
[9] Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013)
Kudo, Masatoshi
Izumi, Namiki
Kokudo, Norihiro
Sakamoto, Michiie
Shiina, Shuichiro
Takayama, Tadatoshi
Tateishi, Ryosuke
Nakashima, Osamu
Murakami, Takamichi
Matsuyama, Yutaka
Takahashi, Arata
Miyata, Hiroaki
Kubo, Shoji
[J]. HEPATOLOGY RESEARCH, 2022, 52 (01) : 5 - 66
[10] Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan
Shimada, M
Takenaka, K
Gion, T
Fujiwara, Y
Kajiyama, K
Maeda, T
Shirabe, K
Nishizaki, T
Yanaga, K
Sugimachi, K
[J]. GASTROENTEROLOGY, 1996, 111 (03) : 720 - 726

← 1 2 →